Literature DB >> 7831432

High 5-HT2 receptor occupancy in clozapine treated patients demonstrated by PET.

A L Nordström1, L Farde, C Halldin.   

Abstract

The clinical benefit of the atypical antipsychotic drug clozapine may be related to a combined effect on D2 and 5-HT2 receptors. To examine the basis for this hypothesis, positron emission tomography (PET) and the radioligand [11C]N-methylspiperone were used to determine cortical 5-HT2 receptor occupancy in three psychotic patients treated with 125 mg, 175mg and 200mg clozapine daily. The uptake of [11C]N-methylspiperone in the frontal cortex was very low compared to that in neuroleptic naive schizophrenic patients. 5-HT2 receptor occupancy calculated in the clozapine treated patients was 84%, 87% and 90%. The results show that clinical treatment with clozapine induces a high 5-HT2 receptor occupancy in psychotic patients at a low dose level.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7831432     DOI: 10.1007/bf02251294

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  12 in total

1.  Antipsychotic drugs, neurotransmitters, and schizophrenia.

Authors:  A Carlsson
Journal:  Am J Psychiatry       Date:  1978-02       Impact factor: 18.112

2.  Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.

Authors:  J Kane; G Honigfeld; J Singer; H Meltzer
Journal:  Arch Gen Psychiatry       Date:  1988-09

3.  An improved synthesis of (3-N-[11C]methyl)spiperone.

Authors:  R F Dannals; H T Ravert; A A Wilson; H N Wagner
Journal:  Int J Rad Appl Instrum A       Date:  1986

4.  Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects.

Authors:  L Farde; A L Nordström; F A Wiesel; S Pauli; C Halldin; G Sedvall
Journal:  Arch Gen Psychiatry       Date:  1992-07

5.  Stereoselective binding of 11C-raclopride in living human brain--a search for extrastriatal central D2-dopamine receptors by PET.

Authors:  L Farde; S Pauli; H Hall; L Eriksson; C Halldin; T Högberg; L Nilsson; I Sjögren; S Stone-Elander
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

6.  In vivo binding of 3H-N-methylspiperone to dopamine and serotonin receptors.

Authors:  J J Frost; A C Smith; M J Kuhar; R F Dannals; H N Wagner
Journal:  Life Sci       Date:  1987-03-09       Impact factor: 5.037

7.  5-HT2 and D2 dopamine receptor occupancy in the living human brain. A PET study with risperidone.

Authors:  S Nyberg; L Farde; L Eriksson; C Halldin; B Eriksson
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

Review 8.  Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia.

Authors:  H Y Meltzer
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

Review 9.  Clozapine: neuroleptic-induced EPS and tardive dyskinesia.

Authors:  D E Casey
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

10.  Important issues in the drug treatment of schizophrenia.

Authors:  J M Davis; C B Schaffer; G A Killian; C Kinard; C Chan
Journal:  Schizophr Bull       Date:  1980       Impact factor: 9.306

View more
  8 in total

Review 1.  Antipsychotic and antidepressive effects of second generation antipsychotics: two different pharmacological mechanisms?

Authors:  Hans-Jürgen Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-06       Impact factor: 5.270

Review 2.  Mechanisms of action of atypical antipsychotic drugs: a critical analysis.

Authors:  B J Kinon; J A Lieberman
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

Review 3.  Olanzapine. Pharmacokinetic and pharmacodynamic profile.

Authors:  J T Callaghan; R F Bergstrom; L R Ptak; C M Beasley
Journal:  Clin Pharmacokinet       Date:  1999-09       Impact factor: 6.447

4.  Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis.

Authors:  Herbert Y Meltzer; Roger Mills; Stephen Revell; Hilde Williams; Ann Johnson; Daun Bahr; Joseph H Friedman
Journal:  Neuropsychopharmacology       Date:  2009-11-11       Impact factor: 7.853

5.  A cross-validation study on the relationship between central D2 receptor occupancy and serum perphenazine concentration.

Authors:  Mirjam Talvik; Anna-Lena Nordström; Niels-Erik Larsen; Aurelija Jucaite; Simon Cervenka; Christer Halldin; Lars Farde
Journal:  Psychopharmacology (Berl)       Date:  2004-03-06       Impact factor: 4.530

6.  Enhancement of latent inhibition by two 5-HT2A receptor antagonists only when given at both pre-exposure and conditioning.

Authors:  L M McDonald; P M Moran; G N Vythelingum; M H Joseph; J D Stephenson; J A Gray
Journal:  Psychopharmacology (Berl)       Date:  2002-08-09       Impact factor: 4.530

Review 7.  5-HT radioligands for human brain imaging with PET and SPECT.

Authors:  Louise M Paterson; Birgitte R Kornum; David J Nutt; Victor W Pike; Gitte M Knudsen
Journal:  Med Res Rev       Date:  2011-06-14       Impact factor: 12.944

Review 8.  On the discovery and development of pimavanserin: a novel drug candidate for Parkinson's psychosis.

Authors:  Uli Hacksell; Ethan S Burstein; Krista McFarland; Roger G Mills; Hilde Williams
Journal:  Neurochem Res       Date:  2014-03-30       Impact factor: 3.996

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.